<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211495</url>
  </required_header>
  <id_info>
    <org_study_id>14/SC/0084</org_study_id>
    <secondary_id>14HH1901</secondary_id>
    <nct_id>NCT02211495</nct_id>
  </id_info>
  <brief_title>ULCERS - Electrical Stimulation in Diabetic Foot Ulceration</brief_title>
  <official_title>Electrical Stimulation in Diabetic Foot Ulceration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesise that use of a medical device, that increases blood flow to the&#xD;
      foot, will speed up ulcer healing in symptomatic diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes affects approximately 347 million people worldwide, and by 2030 the WHO projects&#xD;
      that diabetes will be the 7th leading cause of death. Diabetic foot ulcers are estimated to&#xD;
      occur in 15% of all patients with diabetes, often co-existing with neuropathy and peripheral&#xD;
      vascular disease which compromise the limb's ability to heal. Foot infections in this cohort&#xD;
      are common, and diabetic foot ulcers serve as a portal for infective organisms to enter the&#xD;
      body. Unchecked, infection can spread contiguously to involve underlying tissues, including&#xD;
      bone. A diabetic foot infection is often the pivotal event leading to gangrene and lower&#xD;
      extremity amputation. Diabetes accounts for over one million leg amputations every year, and&#xD;
      represents 60% of all amputations in developed countries.&#xD;
&#xD;
      Due to the potential for rapid progression of infection, and the gravity of potential&#xD;
      complications, diabetic foot problems are handled aggressively in the community, with a low&#xD;
      threshold for referral to secondary care. Out-patient clinics involve a multidisciplinary&#xD;
      team of clinicians, podiatrists and vascular surgeons. Good foot care is taught to all&#xD;
      diabetic patients, and treatment with antibiotics, debridement and revascularisation should&#xD;
      occur as a matter of urgency where appropriate.&#xD;
&#xD;
      The device to be tested mimics the effect of walking by making the foot twitch- it increases&#xD;
      blood flow to the limb and exercises the leg muscles. It is hypothesised that increasing&#xD;
      blood flow to the limb, much as surgical revascularisation, will aid the legs ability to heal&#xD;
      and fight infection. After training, it can be used by patients on themselves and is suitable&#xD;
      for out-patient therapy.&#xD;
&#xD;
      The investigators wish to evaluate both the short- and longer-term effects of a neuromuscular&#xD;
      stimulator on diabetic foot ulceration as a therapeutic intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Day Until 50% Healing of Leg Ulcer</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time to 50% healing of leg ulcer, as measured by volume (3D camera)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (PAID, EQ5D, VAS, SF-12)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Improvement in quality of life questionnaire values, comparing baseline to 6 weeks with treatment PAID (&quot;Problem Areas in Diabetes&quot;) - score 0-80, 0 is no problem, 80 is serious problem EQ5D (standardised instrument for generic quality of life score, https://en.wikipedia.org/wiki/EQ-5D) - combination of different dimensions of health to form an overall index, 1.0 for a perfect state of health, with 0 on the scale representing the state of being dead VAS (&quot;visual analogue scale&quot;) - For pain intensity, the scale is anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100) SF 12 (&quot;short form 12&quot;) - weighted and summed to provide easily interpretable scales for physical and mental health, the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>No device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with best medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GEKO device</intervention_name>
    <description>Placed on the lateral aspect of the knee, when activated it causes the leg to twitch</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Medical Therapy</intervention_name>
    <description>Seen in outpatient clinic for wound care and ongoing advice</description>
    <arm_group_label>Device</arm_group_label>
    <arm_group_label>No device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  18+ years old&#xD;
&#xD;
          -  Type 2 diabetes on best medical therapy&#xD;
&#xD;
          -  Active foot ulceration, present &lt;3 months Exclusion criteria&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Metal implants in the legs (below knee)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kate Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetic Foot Clinic, Praed Street, Paddington</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <results_first_submitted>September 18, 2019</results_first_submitted>
  <results_first_submitted_qc>November 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2020</results_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot</keyword>
  <keyword>Ulcer healing</keyword>
  <keyword>Medical device to increase blood flow in foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Device</title>
          <description>Treated with best medical therapy&#xD;
Best Medical Therapy: Seen in outpatient clinic for wound care and ongoing advice</description>
        </group>
        <group group_id="P2">
          <title>Device</title>
          <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.&#xD;
GEKO device: Placed on the lateral aspect of the knee, when activated it causes the leg to twitch&#xD;
Best Medical Therapy: Seen in outpatient clinic for wound care and ongoing advice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Device</title>
          <description>Medical therapy</description>
        </group>
        <group group_id="B2">
          <title>Device</title>
          <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="56" upper_limit="76"/>
                    <measurement group_id="B2" value="69.5" lower_limit="49" upper_limit="87"/>
                    <measurement group_id="B3" value="67" lower_limit="49" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Day Until 50% Healing of Leg Ulcer</title>
        <description>Time to 50% healing of leg ulcer, as measured by volume (3D camera)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Device</title>
            <description>Medical therapy only.</description>
          </group>
          <group group_id="O2">
            <title>Device</title>
            <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Day Until 50% Healing of Leg Ulcer</title>
          <description>Time to 50% healing of leg ulcer, as measured by volume (3D camera)</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="5"/>
                    <measurement group_id="O2" value="30" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (PAID, EQ5D, VAS, SF-12)</title>
        <description>Improvement in quality of life questionnaire values, comparing baseline to 6 weeks with treatment PAID (&quot;Problem Areas in Diabetes&quot;) - score 0-80, 0 is no problem, 80 is serious problem EQ5D (standardised instrument for generic quality of life score, https://en.wikipedia.org/wiki/EQ-5D) - combination of different dimensions of health to form an overall index, 1.0 for a perfect state of health, with 0 on the scale representing the state of being dead VAS (&quot;visual analogue scale&quot;) - For pain intensity, the scale is anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100) SF 12 (&quot;short form 12&quot;) - weighted and summed to provide easily interpretable scales for physical and mental health, the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Device (Week 0)</title>
            <description>Medical therapy, no device.</description>
          </group>
          <group group_id="O2">
            <title>No Device (Week 6)</title>
            <description>Medical therapy, no device, week 6.</description>
          </group>
          <group group_id="O3">
            <title>Device (Week 0)</title>
            <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg.&#xD;
Week 0</description>
          </group>
          <group group_id="O4">
            <title>Device (Week 6)</title>
            <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week, week 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (PAID, EQ5D, VAS, SF-12)</title>
          <description>Improvement in quality of life questionnaire values, comparing baseline to 6 weeks with treatment PAID (&quot;Problem Areas in Diabetes&quot;) - score 0-80, 0 is no problem, 80 is serious problem EQ5D (standardised instrument for generic quality of life score, https://en.wikipedia.org/wiki/EQ-5D) - combination of different dimensions of health to form an overall index, 1.0 for a perfect state of health, with 0 on the scale representing the state of being dead VAS (&quot;visual analogue scale&quot;) - For pain intensity, the scale is anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 100) SF 12 (&quot;short form 12&quot;) - weighted and summed to provide easily interpretable scales for physical and mental health, the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="14"/>
                    <measurement group_id="O2" value="13" spread="1"/>
                    <measurement group_id="O3" value="21.2" spread="7"/>
                    <measurement group_id="O4" value="17.3" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ5D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".54" spread=".4"/>
                    <measurement group_id="O2" value=".7" spread=".2"/>
                    <measurement group_id="O3" value=".18" spread=".4"/>
                    <measurement group_id="O4" value=".4" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="13"/>
                    <measurement group_id="O2" value="60" spread="14"/>
                    <measurement group_id="O3" value="37" spread="38"/>
                    <measurement group_id="O4" value="55" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" spread="12"/>
                    <measurement group_id="O2" value="67" spread="9"/>
                    <measurement group_id="O3" value="66" spread="14"/>
                    <measurement group_id="O4" value="72" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Device</title>
          <description>Medical therapy, no device.</description>
        </group>
        <group group_id="E2">
          <title>Device</title>
          <description>As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Miss Kate Williams</name_or_title>
      <organization>Imperial College London</organization>
      <email>k.williams@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

